TOP STORIES

• BUSINESS BMS CEO Sees Faster Drug Development as Industry Imperative after COVID Vaccine Feat
  May 25, 2022

• BUSINESS US Business Made or Broke FY2021 Earnings of Big 3 Generic Makers; Nichi-Iko, Sawai Suffer Losses
  May 24, 2022

• REGULATORY 2 mg Pen of Supply-Crippled Ozempic, 3rd Avastin Biosimilar Get Japan Listing
  May 24, 2022

• REGULATORY Japan’s Emergency Approval System Comes into Force, Nod Based on Presumed Efficacy
  May 23, 2022

• REGULATORY MOF Budget Examiner Presses for “Full” Annual Re-Pricing, Stepwise Cut in 2% Buffer Zone If No Reasonable Basis Given
  May 20, 2022

• REGULATORY Chuikyo OKs Listing of 14 Drugs on May 25, Biggest Peak Sales Forecast for Vabysmo
  May 19, 2022

• REGULATORY 4 Drugs Face Zero Premium Rule for Low Cost Disclosures: May Price Listing
  May 19, 2022

• BUSINESS Argenx CEO Sees Big Potential for Vyvgart with 100-Plus Diseases Driven by IgGs; Analysts Peg Peak Sales at US$5-10 Billion
  May 18, 2022

• BUSINESS AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
  May 18, 2022

• ORGANIZATION PhRMA Urges Japan to Exclude Patented Products from Off-Year Re-Pricing in 2023, Create Innovation Ecosystem
  May 17, 2022

• BUSINESS Nichi-Iko Seeks Debt Workout amid US Pipeline Delays and Quality Woes, but President to Stay
  May 16, 2022

• BUSINESS Sumitomo Pharma Likely to Miss 5-Year Biz Targets as COVID Hobbles US Launches
  May 16, 2022

• REGULATORY Japan Clears Bill to Create Emergency Approval System, Enforcement Slated by Month-End
  May 13, 2022

• BUSINESS Shionogi Books 110 Billion Yen Sales for Yet-to-Be-Approved COVID Pill, Vaccine: FY2022 Outlook
  May 12, 2022

• BUSINESS Opdivo Projected to Grow 38% to 155 Billion Yen, but Ono Chief Sees No Re-Pricing
  May 12, 2022

• BUSINESS Jardiance Will Come Back as No. 1 in Japan SGLT2 Space after CKD Launch: NBI Chair
  May 11, 2022

• COMMENTARY Foreign Pharma Growing Vocal against Japan’s Pricing Policy, Flags Return of Drug Lag
  May 10, 2022

• ACADEMIA Difficult-to-Quantify Factors Should Be Reflected in Drug Prices to Establish VBP: Health Economist
  May 9, 2022

• REGULATORY Maruho’s Rozex in Line for Rosacea Nod in Japan
  May 9, 2022

• BUSINESS Astellas Logs 1st Sales Growth in 3 Years in FY2021; Chairman Hatanaka to Bow Out
  April 28, 2022

ページ

• « 先頭
• ‹ Prev
• …
• 72
• 73
• 74
• 75
• 76
• 77
• 78
• 79
• 80
• …
• Next ›
• 最終 »